Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Apr 22;9(4):e94871.
doi: 10.1371/journal.pone.0094871. eCollection 2014.

Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases

Ning Lin  1 , Wei Yan  1 , Kaiming Gao  1 , Yinyi Wang  1 , Junxia Zhang  1 , Yongping You  1
Affiliations
Multicenter Study

Prevalence and clinicopathologic characteristics of the molecular subtypes in malignant glioma: a multi-institutional analysis of 941 cases

Ning Lin et al. PLoS One. .

Abstract

Background: Glioblastoma can be classified into four distinct molecular subtypes (Proneural, Neural, Classical and Mesenchymal), based on gene expression profiling. This study aimed to investigate the prevalence, clinicopathologic features and overall survival (OS) of the four molecular subtypes among all malignant gliomas.

Methods: A total of 941 gene expression arrays with clinical data were obtained from the Rembrandt, GSE16011 and CGGA datasets. Molecular subtypes were predicted with a prediction analysis of microarray.

Results: Among 941 malignant gliomas, 32.73% were Proneural, 15.09% Neural, 19.77% Classical and 32.41% Mesenchymal. The Proneural and Neural subtypes occurred largely in low-grade gliomas, while the Classical and Mesenchymal subtypes were more frequent in high-grade gliomas. A survival analysis showed that the Proneural subtype displayed a good prognosis, Neural had an intermediate correlation with overall survival, Mesenchymal had a worse prognosis than Neural, and Classical had the worst clinical outcome. Furthermore, oligodendrocytomas were preferentially assigned to the Proneural subtype, while the Mesenchymal subtype included a higher percentage of astrocytomas, compared with oligodendrocytomas. Additionally, nearly all classical gliomas harbored EGFR amplifications. Classical anaplastic gliomas have similar clinical outcomes as their glioblastoma counterparts and should be treated more aggressively.

Conclusions: Molecular subtypes exist stably in all histological malignant gliomas subtypes. This could be an important improvement to histological diagnoses for both prognosis evaluations and clinical outcome predictions.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. The prevalence and clinical features of the molecular subtypes in all malignant gliomas.
(A) Distribution of the TCGA molecular subtypes in all malignant gliomas; (B) survival analysis according to the TCGA molecular subtypes in all malignant gliomas.
Figure 2
Figure 2. The prevalence and clinical features of the molecular subtypes in low-grade gliomas.
(A) astrocytomas, (B) oligoastrocytomas and (C) oligodendrocytomas.
Figure 3
Figure 3. The prevalence and clinical features of molecular subtypes in anaplastic gliomas.
(A) astrocytomas, (B) oligoastrocytomas and (C) oligodendrocytomas.
Figure 4
Figure 4. The prevalence and clinical features of the molecular subtypes in glioblastomas.
Figure 5
Figure 5. The prevalence of EGFR amplification in the molecular subtypes of malignant gliomas (A) and the ROC curve of EGFR amplification as a potential diagnostic marker of Classical gliomas (B).
Figure 6
Figure 6. Survival analysis according to the histology and tumor molecular subtypes in high-grade gliomas.
See this image and copyright information in PMC

References

    1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683–2710. - PubMed
    1. Yan W, Zhang W, Jiang T (2011) Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res 30: 58. - PMC - PubMed
    1. Drappatz J, Norden AD, Wen PY (2009) Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother 9: 519–534. - PubMed
    1. Wang Y, Jiang T (2013) Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett 331: 139–146. - PubMed
    1. Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, et al. (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: 9065–9072. - PubMed

Publication types